Abstract Background Ovarian fibrosarcomas are very rare tumors, and therefore, few case ac30s1 studies have evaluated the prognostic factors of this disease.To our knowledge, this study represents the largest study to evaluate the clinical and pathologic factors associated with ovarian fibrosarcoma patients.Methods Thirty-one cases of ovarian fibrosarcoma were retrospectively reviewed, which included medical records for eight patients, and 23 published case reports from 1995 through 2009.Patient treatment regimens included total hysterectomy with bilateral adnexectomy and an omentectomy (BAO) (n = 9), oophorectomy (OR) (n = 8), chemotherapy (CT) (n = 1), BAO followed by chemotherapy (BAO+CT) (n = 11), BAO followed by radiotherapy (BAO+RT) (n = 1), and oophorectomy followed by radiotherapy (OR + RT) (n = 1).Results The patients of this cohort were staged according to the guidelines of the Federation of Gynecology and Obstetrics (FIGO), with 15, 6, 9, and 1 stage I-IV cases identified, respectively.
Mitotic count values were also evaluated from 10 high-power fields (HPFs), and 3 cases had an average mitotic count P = 0.007) and treatment (P = 0.008) were predictive of poor prognosis.Furthermore, patients with stage I tumors that received BAO+CT were associated with a better prognosis.Conclusions Mitotic activity, and cells positive for Ki-67 were identified as important factors in the diagnosis of ovarian fibrosarcoma.
Furthermore, FIGO stage and treatment modalities have the potential to be prognostic vacuum pro vst factors of survival, with BAO followed by adjuvant chemotherapy associated with an improved treatment outcome.